Trial Profile

A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exagamglogene autotemcel (Primary) ; Busulfan; Plerixafor
Indications Sickle cell anaemia
Focus Registrational; Therapeutic Use
Acronyms CLIMB-151
Sponsors Vertex Pharmaceuticals

Most Recent Events

01 Aug 2024 This trial has been suspended in Germany, according to European Clinical Trials Database .
06 Jun 2024 This trial is ongoing in Germany According to against European Clinical Trials Database record.
08 Jan 2024 Status changed from recruiting to active, no longer recruiting, according to CRISPR Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com